STOCK TITAN
  1. Home
  2. News
  3. BPTH

Bio-Path Holdings Inc - BPTH STOCK NEWS

Welcome to our dedicated news page for Bio-Path Holdings (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Path Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Path Holdings's position in the market.

News
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Bio-Path Holdings, Inc. announces the closing of a $1.2 million registered direct offering priced at-the-market under Nasdaq rules. The offering included 375,000 shares of common stock at $3.225 per share and unregistered warrants to purchase up to 375,000 shares at an exercise price of $3.10 per share. The proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
offering
-
News
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Bio-Path Holdings, Inc. announced a $1.2 million registered direct offering priced at-the-market under Nasdaq rules. The offering includes the sale of 375,000 shares of common stock at $3.225 per share and unregistered warrants to purchase up to 375,000 shares at $3.10 per share in a concurrent private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.63%
Tags
offering
-
News
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Rhea-AI Summary
Bio-Path Holdings, Inc. announces the successful completion of the higher dose second cohort in the Phase 1/1b clinical trial of BP1002 for refractory/relapsed Acute Myeloid Leukemia (AML) patients. BP1002 targets the Bcl-2 protein, offering hope for venetoclax-resistant AML patients. The trial aims to evaluate the safety and efficacy of BP1002 in treating patients with treatment options, potentially overcoming resistance mechanisms to venetoclax treatment. The completion of the second dose cohort marks a significant milestone for FDA review, with plans to progress to higher doses and combination therapy segments in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.63%
Tags
clinical trial
News
Bio-Path Holdings Expands Global Patent Portfolio
Rhea-AI Summary
Bio-Path Holdings expands its global patent portfolio to protect its DNAbilize® platform, receiving newly issued patents in Mexico, Australia, and Japan. The company now has a total of 59 issued patents in 21 countries, with additional patents expected this year. The patents cover composition of matter and methods of use for its proprietary technology, providing protection and exclusivity for new protein targets. Bio-Path continues to invest in building protection around its platform to advance its clinical programs and bring new cancer medicines to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
-
News
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Rhea-AI Summary
Bio-Path Holdings, Inc. provides a clinical development update for 2024, highlighting progress in multiple programs including Phase 2 and Phase 1/1b clinical trials for various cancer treatments. The company aims to accelerate regulatory designations to advance studies and file for approvals. Key programs include prexigebersen for Acute Myeloid Leukemia and other solid tumors, BP1002 for relapsed/refractory AML, and BP1003 for advanced solid tumors. Bio-Path also plans to evaluate prexigebersen for obesity treatment. The company emphasizes the importance of molecular biomarkers in enhancing treatment efficacy. Intellectual property protection through composition of matter patents is a key focus for safeguarding proprietary technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none
-
News
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Rhea-AI Summary
Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (BPTH) for Q4 2023, providing valuable insights for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
News
Bio-Path Holdings Reports Full Year 2023 Financial Results
Rhea-AI Summary
Bio-Path Holdings, Inc. (BPTH) announces financial results for 2023, highlighting progress in DNAbilize programs and clinical trials for cancer drugs. The company reported a net loss of $16.1 million, with increased R&D expenses but decreased administrative costs. Recent corporate developments include successful completion of clinical trials for BP1002 in AML, lymphoma, and CLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
earnings
-
News
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
Rhea-AI Summary
Bio-Path Holdings, Inc. (BPTH) will host a conference call to report Q4 and full-year 2023 financial results and provide a business overview on March 8, 2024. The company utilizes DNAbilize® antisense RNAi nanoparticle technology for cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
earnings
-
News
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Rhea-AI Summary
Bio-Path Holdings, Inc. (NASDAQ: BPTH) announces a reverse stock split at a ratio of 1-for-20 effective on February 22, 2024. The common stock will begin trading on a split-adjusted basis on February 23, 2024, under the existing symbol 'BPTH'. The split aims to reduce outstanding shares from 12,352,664 to approximately 617,833 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
stock split
News
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Rhea-AI Summary
Bio-Path Holdings, Inc. (BPTH) completes first dose cohort of Phase 1 clinical trial for BP1002, a potential treatment targeting Bcl-2 protein for refractory/relapsed lymphoma and CLL patients. Preclinical studies show promising results, with the potential for combination therapy with approved agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
clinical trial
Stock BPTH logo
Bio-Path Holdings Inc

Nasdaq:BPTH

BPTH Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BPTH Stock Data

2.30M
628.47k
0.23%
3.73%
9.93%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Bellaire

About BPTH

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen